Health Care Down on Retreat from Biotech -- Health Care Roundup

Dow Jones04-11 05:20

Health-care companies fell as traders retreated from high-risk areas, including biotech.

Shares of Replimune Group slid after an application for an experimental skin cancer drug was rejected by the Food and Drug Administration for the second time.

The iShares Nasdaq Biotech index exchange-traded fund, a basket of major biotechs, fell by 1.6%.

Swiss drug maker Roche is likely to face currency headwinds in its earnings report, said analysts at brokerage UBS, in a note to clients.

Another Swiss drug firm, Novartis, will likely direct investors' attention to its late-stage drug pipeline, given that it has already warned of weak earnings in the first half, said the UBS analysts.

Write to Rob Curran at rob.curran@dowjones.com

(END) Dow Jones Newswires

April 10, 2026 17:20 ET (21:20 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2626143239?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-11 05:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2626143239","market":"other","top_or_hot":-1,"title":"Health Care Down on Retreat from Biotech -- Health Care Roundup","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  Health-care companies fell as traders retreated from high-risk areas, including biotech. \n</p>\n<p>\n  Shares of Replimune Group slid after an application for an experimental skin cancer drug was rejected by the Food and Drug Administration for the second time. \n</p>\n<p>\n  The <a href=\"https://laohu8.com/S/EEMA\">iShares</a> Nasdaq Biotech index exchange-traded fund, a basket of major biotechs, fell by 1.6%. \n</p>\n<p>\n  Swiss drug maker Roche is likely to face currency headwinds in its earnings report, said analysts at brokerage UBS, in a note to clients. \n</p>\n<p>\n  Another Swiss drug firm, Novartis, will likely direct investors' attention to its late-stage drug pipeline, given that it has already warned of weak earnings in the first half, said the UBS analysts. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Rob Curran at rob.curran@dowjones.com \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 10, 2026 17:20 ET (21:20 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Health Care Down on Retreat from Biotech -- Health Care Roundup</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHealth Care Down on Retreat from Biotech -- Health Care Roundup\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-04-11 05:20</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  Health-care companies fell as traders retreated from high-risk areas, including biotech. \n</p>\n<p>\n  Shares of Replimune Group slid after an application for an experimental skin cancer drug was rejected by the Food and Drug Administration for the second time. \n</p>\n<p>\n  The <a href=\"https://laohu8.com/S/EEMA\">iShares</a> Nasdaq Biotech index exchange-traded fund, a basket of major biotechs, fell by 1.6%. \n</p>\n<p>\n  Swiss drug maker Roche is likely to face currency headwinds in its earnings report, said analysts at brokerage UBS, in a note to clients. \n</p>\n<p>\n  Another Swiss drug firm, Novartis, will likely direct investors' attention to its late-stage drug pipeline, given that it has already warned of weak earnings in the first half, said the UBS analysts. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Rob Curran at rob.curran@dowjones.com \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 10, 2026 17:20 ET (21:20 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2626143239","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2626143239","pubTimestamp":1775856000,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Health-care companies fell as traders retreated from high-risk areas, including biotech.Shares of Replimune Group slid after an application for an experimental skin cancer drug was rejected by the Food and Drug Administration for the second time.The iShares Nasdaq Biotech index exchange-traded fund, a basket of major biotechs, fell by 1.6%.Swiss drug maker Roche is likely to face currency headwinds in its earnings report, said analysts at brokerage UBS, in a note to clients.Another Swiss drug firm, Novartis, will likely direct investors' attention to its late-stage drug pipeline, given that it has already warned of weak earnings in the first half, said the UBS analysts.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4588":"碎股","XLV":"健康照护类股ETF-SPDR","BK4581":"高盛持仓","XBI":"SPDR S&P Biotech ETF","LABU":"三倍做多标普生物-Direxion"},"translate_title":"医疗保健因生物技术撤退而下降——医疗保健综述","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XBI":1.5,"XLV":1.5,"LABU":0.6},"content_text":"Health-care companies fell as traders retreated from high-risk areas, including biotech. \n\n\n  Shares of Replimune Group slid after an application for an experimental skin cancer drug was rejected by the Food and Drug Administration for the second time. \n\n\n  The iShares Nasdaq Biotech index exchange-traded fund, a basket of major biotechs, fell by 1.6%. \n\n\n  Swiss drug maker Roche is likely to face currency headwinds in its earnings report, said analysts at brokerage UBS, in a note to clients. \n\n\n  Another Swiss drug firm, Novartis, will likely direct investors' attention to its late-stage drug pipeline, given that it has already warned of weak earnings in the first half, said the UBS analysts. \n\n\n \n\n\n  Write to Rob Curran at rob.curran@dowjones.com \n\n\n  (END) Dow Jones Newswires\n\n\n  April 10, 2026 17:20 ET (21:20 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2626143239","isCrawlerRequest":true}